Listed

Semnur Pharmaceuticals, Inc.

SMNROTCCIK 1913577HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$4.2m, Q2 FY2026
Net income−$4.3m, Q2 FY2026
Semnur Pharmaceuticals, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$mnot reportednot reportednot reportednot reported0.2Research and development, Q3 FY2024, three months to 2024-09-30$233.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure0.2Research and development, Q4 FY2024, three months to 2024-12-31$235.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-27, accession 0001193125-26-082642. Derived: 12-month figure less the 9-month figure.Report this figure0.2Research and development, Q1 FY2025, three months to 2025-03-31$187.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001193125-26-221896.Report this figure0.5Research and development, Q2 FY2025, three months to 2025-06-30$502.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure1.1Research and development, Q3 FY2025, three months to 2025-09-30$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure0.7Research and development, Q4 FY2025, three months to 2025-12-31$714.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-27, accession 0001193125-26-082642. Derived: 12-month figure less the 9-month figure.Report this figure1.3Research and development, Q1 FY2026, three months to 2026-03-31$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001193125-26-221896.Report this figure1.2Research and development, Q2 FY2026, three months to 2026-06-30$1.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure
Operating income$m(0.5)Operating income, Q3 FY2023, three months to 2023-09-30−$505.9k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-19, accession 0001213900-24-100217.Report this figure(0.2)Operating income, Q4 FY2023, three months to 2023-12-31−$182.5k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-04-02, accession 0001213900-25-027319. Derived: 12-month figure less the 9-month figure.Report this figure(0.4)Operating income, Q1 FY2024, three months to 2024-03-31−$368.3k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-16, accession 0001213900-25-044889.Report this figure(0.2)Operating income, Q2 FY2024, three months to 2024-06-30−$168.2k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-15, accession 0001213900-25-077047.Report this figure(1.3)Operating income, Q3 FY2024, three months to 2024-09-30−$1.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure(0.8)Operating income, Q4 FY2024, three months to 2024-12-31−$776.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001193125-26-082642. Derived: 12-month figure less the 9-month figure.Report this figure(0.7)Operating income, Q1 FY2025, three months to 2025-03-31−$665.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001193125-26-221896.Report this figure(1.0)Operating income, Q2 FY2025, three months to 2025-06-30−$999.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure(153)Operating income, Q3 FY2025, three months to 2025-09-30−$152.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure(6.2)Operating income, Q4 FY2025, three months to 2025-12-31−$6.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001193125-26-082642. Derived: 12-month figure less the 9-month figure.Report this figure(4.6)Operating income, Q1 FY2026, three months to 2026-03-31−$4.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001193125-26-221896.Report this figure(4.2)Operating income, Q2 FY2026, three months to 2026-06-30−$4.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure
Interest expense$m0.0Interest expense, Q3 FY2023, three months to 2023-09-30$14.7k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-09, accession 0001213900-23-085292.Report this figure0.0Interest expense, Q4 FY2023, three months to 2023-12-31$17.7k. XBRL concept us-gaap:InterestExpense. 10-K filed 2025-04-02, accession 0001213900-25-027319. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2024, three months to 2024-03-31$21.3k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-05-16, accession 0001213900-25-044889.Report this figure0.0Interest expense, Q2 FY2024, three months to 2024-06-30$23.1k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-08-15, accession 0001213900-25-077047.Report this figure0.0Interest expense, Q3 FY2024, three months to 2024-09-30$25.2k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2024-11-19, accession 0001213900-24-100217.Report this figure0.0Interest expense, Q4 FY2024, three months to 2024-12-31$26.7k. XBRL concept us-gaap:InterestExpense. 10-K filed 2025-04-02, accession 0001213900-25-027319. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2025, three months to 2025-03-31$27.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-05-16, accession 0001213900-25-044889.Report this figure0.0Interest expense, Q2 FY2025, three months to 2025-06-30$28.3k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-08-15, accession 0001213900-25-077047.Report this figurenot reportednot reportednot reported0.1Interest expense, Q2 FY2026, three months to 2026-06-30$123.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure
Net income$m0.6Net income, Q3 FY2023, three months to 2023-09-30$630.6k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-19, accession 0001213900-24-100217.Report this figure0.6Net income, Q4 FY2023, three months to 2023-12-31$632.5k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-04-02, accession 0001213900-25-027319.Report this figure(1.5)Net income, Q1 FY2024, three months to 2024-03-31−$1.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure(1.1)Net income, Q2 FY2024, three months to 2024-06-30−$1.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure(1.3)Net income, Q3 FY2024, three months to 2024-09-30−$1.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure(0.2)Net income, Q4 FY2024, three months to 2024-12-31−$167.3k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-04-02, accession 0001213900-25-027319.Report this figure(0.7)Net income, Q1 FY2025, three months to 2025-03-31−$665.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure(1.0)Net income, Q2 FY2025, three months to 2025-06-30−$999.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure(153)Net income, Q3 FY2025, three months to 2025-09-30−$152.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure(6.2)Net income, Q4 FY2025, three months to 2025-12-31−$6.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001193125-26-082642. Derived: 12-month figure less the 9-month figure.Report this figure(4.6)Net income, Q1 FY2026, three months to 2026-03-31−$4.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure(4.3)Net income, Q2 FY2026, three months to 2026-06-30−$4.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure
Diluted EPS$ per sharenot reportednot reportednot reportednot reported(0.01)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figurenot reported(0.01)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001193125-26-221896.Report this figure(0.01)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure(0.76)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.76 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figurenot reported(0.02)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001193125-26-221896.Report this figure(0.02)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure
Basic EPS$ per sharenot reportednot reportednot reportednot reported(0.01)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figurenot reported(0.01)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001193125-26-221896.Report this figure(0.01)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure(0.76)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.76 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figurenot reported(0.02)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001193125-26-221896.Report this figure(0.02)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure

Balance sheet

Cash and equivalents$39.0k, Q2 FY2026
Shareholders' equity−$29.7m, Q2 FY2026
Semnur Pharmaceuticals, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m0.0Cash and equivalents, Q3 FY2023, at 2023-09-30$13.5k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0001213900-23-085292.Report this figure0.2Cash and equivalents, FY2023, at 2023-12-31$204.5k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-22, accession 0001213900-24-045702.Report this figure0.0Cash and equivalents, Q1 FY2024, at 2024-03-31$1.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-22, accession 0001213900-24-045702.Report this figure0.0Cash and equivalents, Q2 FY2024, at 2024-06-30$1.5k. XBRL concept us-gaap:Cash. 10-Q filed 2024-08-19, accession 0001213900-24-070799.Report this figure0.0Cash and equivalents, Q3 FY2024, at 2024-09-30$14.3k. XBRL concept us-gaap:Cash. 10-Q filed 2024-11-19, accession 0001213900-24-100217.Report this figure0.0Cash and equivalents, FY2024, at 2024-12-31$12.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-27, accession 0001193125-26-082642.Report this figure0.0Cash and equivalents, Q1 FY2025, at 2025-03-31$2.7k. XBRL concept us-gaap:Cash. 10-Q filed 2025-05-16, accession 0001213900-25-044889.Report this figurenot reported0.1Cash and equivalents, Q3 FY2025, at 2025-09-30$85.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure0.0Cash and equivalents, FY2025, at 2025-12-31$20.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure0.1Cash and equivalents, Q1 FY2026, at 2026-03-31$103.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-13, accession 0001193125-26-221896.Report this figure0.0Cash and equivalents, Q2 FY2026, at 2026-06-30$39.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure
Current assets$m0.0Current assets, Q3 FY2023, at 2023-09-30$35.6k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0001213900-23-085292.Report this figure0.2Current assets, FY2023, at 2023-12-31$209.4k. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-04-02, accession 0001213900-25-027319.Report this figure0.1Current assets, Q1 FY2024, at 2024-03-31$65.4k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-22, accession 0001213900-24-045702.Report this figure0.0Current assets, Q2 FY2024, at 2024-06-30$43.8k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-19, accession 0001213900-24-070799.Report this figure0.0Current assets, Q3 FY2024, at 2024-09-30$35.4k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-19, accession 0001213900-24-100217.Report this figure6.0Current assets, FY2024, at 2024-12-31$6.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-27, accession 0001193125-26-082642.Report this figure0.0Current assets, Q1 FY2025, at 2025-03-31$2.7k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-16, accession 0001213900-25-044889.Report this figure0.0Current assets, Q2 FY2025, at 2025-06-30$14.1k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-15, accession 0001213900-25-077047.Report this figure0.1Current assets, Q3 FY2025, at 2025-09-30$85.0k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure0.6Current assets, FY2025, at 2025-12-31$596.0k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure1.2Current assets, Q1 FY2026, at 2026-03-31$1.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-13, accession 0001193125-26-221896.Report this figure1.2Current assets, Q2 FY2026, at 2026-06-30$1.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure
Total assets$m90.1Total assets, Q3 FY2023, at 2023-09-30$90.1m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0001213900-23-085292.Report this figure50.7Total assets, FY2023, at 2023-12-31$50.7m. XBRL concept us-gaap:Assets. 10-K filed 2025-04-02, accession 0001213900-25-027319.Report this figure51.3Total assets, Q1 FY2024, at 2024-03-31$51.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-22, accession 0001213900-24-045702.Report this figure52.1Total assets, Q2 FY2024, at 2024-06-30$52.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-19, accession 0001213900-24-070799.Report this figure8.9Total assets, Q3 FY2024, at 2024-09-30$8.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-19, accession 0001213900-24-100217.Report this figure6.7Total assets, FY2024, at 2024-12-31$6.7m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-27, accession 0001193125-26-082642.Report this figure9.1Total assets, Q1 FY2025, at 2025-03-31$9.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-16, accession 0001213900-25-044889.Report this figure0.6Total assets, Q2 FY2025, at 2025-06-30$562.5k. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-15, accession 0001213900-25-077047.Report this figure0.8Total assets, Q3 FY2025, at 2025-09-30$774.0k. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure1.3Total assets, FY2025, at 2025-12-31$1.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure2.0Total assets, Q1 FY2026, at 2026-03-31$2.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-13, accession 0001193125-26-221896.Report this figure1.9Total assets, Q2 FY2026, at 2026-06-30$1.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure
Current liabilities$m5.1Current liabilities, Q3 FY2023, at 2023-09-30$5.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0001213900-23-085292.Report this figure5.6Current liabilities, FY2023, at 2023-12-31$5.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-04-02, accession 0001213900-25-027319.Report this figure6.0Current liabilities, Q1 FY2024, at 2024-03-31$6.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-22, accession 0001213900-24-045702.Report this figure6.3Current liabilities, Q2 FY2024, at 2024-06-30$6.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-19, accession 0001213900-24-070799.Report this figure6.6Current liabilities, Q3 FY2024, at 2024-09-30$6.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-19, accession 0001213900-24-100217.Report this figure0.0Current liabilities, FY2024, at 2024-12-31$35.0k. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-27, accession 0001193125-26-082642.Report this figure7.9Current liabilities, Q1 FY2025, at 2025-03-31$7.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-16, accession 0001213900-25-044889.Report this figure8.3Current liabilities, Q2 FY2025, at 2025-06-30$8.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-15, accession 0001213900-25-077047.Report this figure10.0Current liabilities, Q3 FY2025, at 2025-09-30$10.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure10.2Current liabilities, FY2025, at 2025-12-31$10.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure10.4Current liabilities, Q1 FY2026, at 2026-03-31$10.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-13, accession 0001193125-26-221896.Report this figure10.7Current liabilities, Q2 FY2026, at 2026-06-30$10.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure
Total liabilities$m8.0Total liabilities, Q3 FY2023, at 2023-09-30$8.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0001213900-23-085292.Report this figure8.5Total liabilities, FY2023, at 2023-12-31$8.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-04-02, accession 0001213900-25-027319.Report this figure8.9Total liabilities, Q1 FY2024, at 2024-03-31$8.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-22, accession 0001213900-24-045702.Report this figure9.2Total liabilities, Q2 FY2024, at 2024-06-30$9.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-19, accession 0001213900-24-070799.Report this figure9.5Total liabilities, Q3 FY2024, at 2024-09-30$9.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-19, accession 0001213900-24-100217.Report this figure49.5Total liabilities, FY2024, at 2024-12-31$49.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-27, accession 0001193125-26-082642.Report this figure10.7Total liabilities, Q1 FY2025, at 2025-03-31$10.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-16, accession 0001213900-25-044889.Report this figure11.2Total liabilities, Q2 FY2025, at 2025-06-30$11.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-15, accession 0001213900-25-077047.Report this figure15.4Total liabilities, Q3 FY2025, at 2025-09-30$15.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure22.1Total liabilities, FY2025, at 2025-12-31$22.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure27.3Total liabilities, Q1 FY2026, at 2026-03-31$27.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-13, accession 0001193125-26-221896.Report this figure31.6Total liabilities, Q2 FY2026, at 2026-06-30$31.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure
Shareholders' equity$m(7.9)Shareholders' equity, Q3 FY2023, at 2023-09-30−$7.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-19, accession 0001213900-24-100217.Report this figure(38.1)Shareholders' equity, FY2023, at 2023-12-31−$38.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-27, accession 0001193125-26-082642.Report this figure(39.6)Shareholders' equity, Q1 FY2024, at 2024-03-31−$39.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure(40.7)Shareholders' equity, Q2 FY2024, at 2024-06-30−$40.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure(42.0)Shareholders' equity, Q3 FY2024, at 2024-09-30−$42.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure(42.8)Shareholders' equity, FY2024, at 2024-12-31−$42.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure(43.4)Shareholders' equity, Q1 FY2025, at 2025-03-31−$43.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure(44.4)Shareholders' equity, Q2 FY2025, at 2025-06-30−$44.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure(14.6)Shareholders' equity, Q3 FY2025, at 2025-09-30−$14.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure(20.8)Shareholders' equity, FY2025, at 2025-12-31−$20.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure(25.3)Shareholders' equity, Q1 FY2026, at 2026-03-31−$25.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure(29.7)Shareholders' equity, Q2 FY2026, at 2026-06-30−$29.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure

Cash flow

Operating cash flow−$2.1m, Q2 FY2026
Share repurchases$0, Q4 FY2024
Semnur Pharmaceuticals, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(75.7)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$75.7k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-19, accession 0001213900-24-100217. Derived: 9-month figure less the 6-month figure.Report this figure(159)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$159.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-04-02, accession 0001213900-25-027319. Derived: 12-month figure less the 9-month figure.Report this figure(374)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$374.2k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-16, accession 0001213900-25-044889.Report this figure(115)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$114.5k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-15, accession 0001213900-25-077047. Derived: 6-month figure less the 3-month figure.Report this figure(2,995)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$3.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-277536. Derived: 9-month figure less the 6-month figure.Report this figure(1,407)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$1.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001193125-26-082642. Derived: 12-month figure less the 9-month figure.Report this figure(399)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$399.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001193125-26-221896.Report this figure268Operating cash flow, Q2 FY2025, three months to 2025-06-30$268.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001193125-26-342594. Derived: 6-month figure less the 3-month figure.Report this figure(2,131)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$2.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-277536. Derived: 9-month figure less the 6-month figure.Report this figure(3,605)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$3.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001193125-26-082642. Derived: 12-month figure less the 9-month figure.Report this figure(2,670)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$2.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001193125-26-221896.Report this figure(2,138)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$2.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001193125-26-342594. Derived: 6-month figure less the 3-month figure.Report this figure
Share repurchases$knot reportednot reportednot reportednot reportednot reported0.0Share repurchases, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2025-04-02, accession 0001213900-25-027319. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)230.21m, Q2 FY2026
Semnur Pharmaceuticals, Inc., shares, quarterly
Line itemUnitQ3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares200Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30200,000,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure200Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31200,000,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001193125-26-221896.Report this figure200Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30200,000,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure202Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30201,686,617 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001193125-25-277536.Report this figure230Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31230,209,142 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001193125-26-221896.Report this figure230Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30230,209,142 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure

Shares outstanding: 230.21mShares outstanding, period not labelled, at 2026-08-10230,209,142 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342594.Report this figure at Aug 10, 2026, from the cover of the 10-Q filed Aug 10, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. Listed shows no prices and gives no investment advice.